Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ NDUFB9 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA560110
Description
Immunogen sequence: FWYRQHPQPY IFPDSPGGTS YERYDCYKVP EWCLDDWHPS EKAMYPDYFA KREQWKKLRR ESWEREVKQL Q Highest antigen sequence identity to the following orthologs: Mouse - 89%, Rat - 87%.
LYRM3, also known as NADH dehydrogenase (ubiquinone) 1 beta subcomplex 9 (NDUFB9), is a ubiquitously expressed LYR-motif containing protein. It has been suggested to be a candidate gene for the branchio-oto-renal (BOR) syndrome, which is characterized by branchial and renal abnormalities and heredity deafness disorders. Other than its LYR-motif, LYRM3 appears to have no functional or structural relationship to either LYRM1 or LYRM2.
Specifications
NDUFB9 | |
Polyclonal | |
Unconjugated | |
Ndufb9 | |
1190008J14Rik; B22; CI-B22; complex I B22 subunit; complex I-B22; EGK_19260; LYR motif-containing protein 3; LYRM3; NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9; NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 22kDa; NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9; NADH:ubiquinone oxidoreductase subunit B9; NADH-ubiquinone oxidoreductase B22 subunit; NDUFB9; UQOR22 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
299954, 4715, 66218 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
0.05 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q9CQJ8, Q9Y6M9 | |
Ndufb9 | |
Recombinant protein corresponding to Human NDUFB9. Recombinant protein control fragment (Product #RP-100162). | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction